The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.

The blood screening market plays a critical role in ensuring the safety and quality of blood used for transfusions and medical procedures. It involves the detection of infectious agents such as HIV, hepatitis B and C, and other transfusion-transmissible infections, helping to prevent disease transmission. The market is driven by increasing awareness of blood safety, rising demand for blood donations, and technological advancements in screening methods such as nucleic acid testing and rapid diagnostics. With growing healthcare investments and supportive government initiatives, the blood screening market is expanding globally, particularly in emerging economies. As the need for accurate and efficient blood testing continues to rise, the market is expected to experience sustained growth across various healthcare settings.

Tariff Impact Analysis for Blood Screening Market:

https://www.fortunebusinessinsights.com/blood-screening-market-102552

Market Segmentation:

• The blood screening market is segmented by technology into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, and chemiluminescence immunoassay (CLIA).
• Based on product type, the blood screening market includes reagents & kits, instruments, and software solutions.
• By end user, the market is divided into blood banks, hospitals, diagnostic laboratories, and plasma centers.
• The blood screening market can also be segmented by application such as infectious disease detection, blood group typing, and genetic disorder screening.

List Of Key Companies Profiled:

• Bio-Rad Laboratories, Inc.
• Grifols, S.A.
• Hoffmann-La Roche
• Ortho Clinical Diagnostics
• BD